IPP Bureau

RedHill Biopharma advances RHB-102 as once-daily oral therapy to combat GLP-1 side effects
RedHill Biopharma advances RHB-102 as once-daily oral therapy to combat GLP-1 side effects

By IPP Bureau - January 06, 2026

The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation

PathoCare Holdings valued at $1.75 billion following major third-party tender offer
PathoCare Holdings valued at $1.75 billion following major third-party tender offer

By IPP Bureau - January 06, 2026

The company previously completed a $150 million venture investment, acquisition, and recapitalization

Nia Therapeutics unveils first implantable brain interface for memory disorders
Nia Therapeutics unveils first implantable brain interface for memory disorders

By IPP Bureau - January 06, 2026

The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices

Singapore clears AI bladder cancer detection tool
Singapore clears AI bladder cancer detection tool

By IPP Bureau - January 06, 2026

CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes

Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs
Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs

By IPP Bureau - January 06, 2026

Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments

Valneva and Serum Institute end chikungunya vaccine partnership
Valneva and Serum Institute end chikungunya vaccine partnership

By IPP Bureau - January 06, 2026

Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries

BioInvent’s experimental combo shows promise in hard-to-treat ovarian cancer
BioInvent’s experimental combo shows promise in hard-to-treat ovarian cancer

By IPP Bureau - January 06, 2026

Pembrolizumab has shown meaningful benefit only when combined with chemotherapy

Abbott unveils Libre Assist to help meal management in diabetics
Abbott unveils Libre Assist to help meal management in diabetics

By IPP Bureau - January 06, 2026

Abbott’s latest innovation promises to shift diabetes management from reactive to proactive

Jaguar Health wins $240,000 FDA grant to advance dog cancer diarrhea treatment
Jaguar Health wins $240,000 FDA grant to advance dog cancer diarrhea treatment

By IPP Bureau - January 05, 2026

The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1

FDA nod to first-ever treatment for deadly post-transplant complication TA-TMA
FDA nod to first-ever treatment for deadly post-transplant complication TA-TMA

By IPP Bureau - January 05, 2026

The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement

FDA delays Corcept’s hypertension drug, seeks more evidence
FDA delays Corcept’s hypertension drug, seeks more evidence

By IPP Bureau - January 05, 2026

The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence

FDA flags uncertainty over PFAS in cosmetics, calls for more research
FDA flags uncertainty over PFAS in cosmetics, calls for more research

By IPP Bureau - January 05, 2026

Our scientists found that toxicological data for most PFAS are incomplete or unavailable, leaving significant uncertainty about consumer safety

Exports of AYUSH and herbal products touches US$ 689 million in 2024–25
Exports of AYUSH and herbal products touches US$ 689 million in 2024–25

By IPP Bureau - January 05, 2026

India’s traditional medicine systems have also earned formal recognition in key bilateral trade agreements

Indian Vice President calls for global recognition of traditional medicine
Indian Vice President calls for global recognition of traditional medicine

By IPP Bureau - January 05, 2026

He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world

FibroBiologics moves experimental psoriasis therapy into FDA review
FibroBiologics moves experimental psoriasis therapy into FDA review

By IPP Bureau - January 04, 2026

The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline

Latest Stories

Interviews

Packaging